Nordic Life Science 1
TOP STORIES BUSINESS Umear Naseem, founder & CEO,
Aplex Bio Mats Nilsson, professor, SciLifeLab from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives to syringes and pen injectors, by co-creating new devices that safely and effectively deliver biologic medicines through oral administration. This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development. The new agreement extends the collaboration through 2026, expanding the scope to encompass the creation and integration of bioelectronics, biosensors and stimuli-responsive delivery devices. on research in collaboration with Professor Mats Nilsson’s laboratory at SciLifeLab. The company is based in Stockholm at Karolinska Institutet (KI) campus and is part of KI Innovations. The company’s solution enables laboratories to extract massive amounts of information from valuable samples by detecting more than 100 biomarkers in each sample with minimal added effort and costs, while maintaining simple workflows. Current solutions are typically limited to around five simultaneous targets that can be analyzed at once. Results are generated instantly in a single step using conventional laboratory equipment, avoiding the need for sequencing or other complex solutions. “A simple and scalable technology like Aplex Bio’s multiplex technology, allowing simultaneous probing of tens to hundreds of target molecules in a single step, combined with extreme sensitivity and single nucleotide specificity will surely become a game-changer for many molecular diagnostic applications,” says Mats Nilsson, professor, SciLifeLab. Marcus Schindler, CSO, Novo Nordisk 14 NORDICLIFESCIENCE.ORG